Holen Sie sich die Stockscreener-App
3.64
2.82%
0.10
Handel nachbörslich:
3.62
-0.02
-0.55%
Schlusskurs vom Vortag:
$3.54
Offen:
$3.62
24-Stunden-Volumen:
3.56M
Relative Volume:
2.04
Marktkapitalisierung:
$378.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.01M
KGV:
-1.7519
EPS:
-2.0778
Netto-Cashflow:
$-131.32M
1W Leistung:
+1.11%
1M Leistung:
+12.35%
6M Leistung:
+6.12%
1J Leistung:
+32.85%
1-Tages-Spanne:
$3.485
$3.76
1-Wochen-Bereich:
$3.39
$3.845
52-Wochen-Spanne:
$2.22
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Firmenname
Larimar Therapeutics Inc
Sektor
Branche
Telefon
844-511-9056
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.64 | 378.13M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-29 | Eingeleitet | Truist | Buy |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-03 | Eingeleitet | Wedbush | Outperform |
| 2024-10-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-03 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-19 | Eingeleitet | Guggenheim | Buy |
| 2022-02-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-02-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
Larimar Therapeutics Inc (LRMR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
Larimar Therapeutics Inc (LRMR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Larimar Therapeutics Inc (LRMR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Larimar Therapeutics (LRMR) Slides 3.6%: Technical Support Test in FocusTriple Bottom - newsline.com
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Friedreich's Ataxia: The Search For A True Disease-Modifying TherapyCan Larimar Deliver? - RTTNews
Larimar Therapeutics (LRMR) Faces Headwinds as Stock Slides 2.21% to $3.10Momentum Surge Alerts - newsline.com
LRMR Q1 2026 Earnings: EPS Surprise of 43% as Loss Narrows, Stock SlidesPost-Announcement Reaction - newsline.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Q1 2026 Earnings: EPS Surprise of 43.19% as Net Loss Narrower Than ExpectedProfit Growth Outlook - newsline.com
Larimar Therapeutics (LRMR) Slides 4.3% as Selling Pressure Tests Key SupportFRAMA Signal - newsline.com
Larimar Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Operational ProgressRevenue Warning Signal - newsline.com
Larimar Therapeutics (LRMR): Shares Hold Steady Near Support as Consolidation ContinuesBollinger Band - newsline.com
LRMR Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Pipeline Progress ContinuesEarnings Forecast Report - thelegaladvocate.com
J.P. Morgan Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $9 - Moomoo
JP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight Recommendation - MSN
LRMR Initiates Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
JPMorgan Initiates Larimar Therapeutics at Overweight With $9 Price Target - marketscreener.com
JPMorgan initiates Larimar Therapeutics stock at Overweight By Investing.com - Investing.com UK
JPMorgan initiates Larimar Therapeutics stock at Overweight - Investing.com India
80,590,392 Common Stock of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Stock Options of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Pre-Funded Warrants of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Larimar Therapeutics (LRMR) Edges Lower as Stock Tests Key Support ZoneComposite Profile - newsline.com
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - MSN
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options - Stock Titan
Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics stockholders approve board elections and share increase By Investing.com - Investing.com Nigeria
Larimar Therapeutics stockholders approve board elections and share increase - Investing.com
Larimar Shareholders Approve Governance and Capital Structure Changes - TipRanks
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase - Stock Titan
LRMR Maintained by Wedbush -- Price Target Lowered to $12.00 - GuruFocus
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Larimar Therapeutics Price Target Cut to $12.00/Share From $13.00 by Wedbush - Moomoo
Larimar Therapeutics (LRMR) surges on FDA breakthrough therapy designation - MSN
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Number of shareholders of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Wedbush Adjusts Larimar Therapeutics Price Target to $12 From $13, Maintains Outperform Rating - Moomoo
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress - The Globe and Mail
Exploring US High Growth Tech Stocks This May 2026 - Yahoo Finance
Citizens reiterates Larimar Therapeutics stock rating on FDA progress By Investing.com - Investing.com South Africa
Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):